Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice

Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice

Interleukin (IL)-17 is emerging as an important cytokine in vaccine-induced protection against tuberculosis disease in animal models. Here we show that compared to parenteral delivery, BCG delivered mucosally enhances cytokine production, including interferon gamma and IL-17, in the lungs. Furthermo...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Griffiths, K, Stylianou, E, Poyntz, H, Betts, G, Fletcher, H, McShane, H
Natura:	Journal article
Lingua:	English
Pubblicazione:	Public Library of Science 2013

Documenti analoghi

Th1/Th17 cell induction following vaccination with the novel tuberculosis vaccine MVA85A and their role in Mycobacterium tuberculosis challenge
di: Griffiths, K, et al.
Pubblicazione: (2011)

Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb)
di: Marsay, L, et al.
Pubblicazione: (2013)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis
di: Poyntz, H, et al.
Pubblicazione: (2014)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis.
di: Poyntz, H, et al.
Pubblicazione: (2014)

Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb).
di: Marsay, L, et al.
Pubblicazione: (2013)

Evaluation of immunological mechanisms induced by Mycobacterium avium exposure and the effect upon pre-existing BCG immunity
di: Poyntz, H, et al.
Pubblicazione: (2011)

Assessing the immunogenic and protective potential of different viral vector regimes, in the mouse model of tuberculosis infection
di: Stylianou, E, et al.
Pubblicazione: (2011)

Insights and challenges in tuberculosis vaccine development
di: McShane, H
Pubblicazione: (2019)

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
di: Stylianou, E, et al.
Pubblicazione: (2019)

Tuberculosis vaccines: Progress and challenges
di: Checkley, A, et al.
Pubblicazione: (2011)

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
di: Stylianou, E, et al.
Pubblicazione: (2015)

Vaccine strategies against tuberculosis
di: H McShane
Pubblicazione: (2009-03-01)

A New Vaccine for Tuberculosis: The Challenges of Development and Deployment
di: Fletcher, H, et al.
Pubblicazione: (2009)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
di: Griffiths, K, et al.
Pubblicazione: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
di: Griffiths, K, et al.
Pubblicazione: (2011)

Vaccines for tuberculosis
di: McShane, H
Pubblicazione: (2013)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
di: Minassian, A, et al.
Pubblicazione: (2011)

Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
di: Christopher J. De Voss, et al.
Pubblicazione: (2025-02-01)

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
di: Vordermeier, H, et al.
Pubblicazione: (2009)

Tuberculosis vaccines: progress and challenges.
di: Checkley, A, et al.
Pubblicazione: (2011)

Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice.
di: Forbes, E, et al.
Pubblicazione: (2008)

Vaccination with an Attenuated Ferritin Mutant Protects Mice against Virulent Mycobacterium tuberculosis
di: Selvakumar Subbian, et al.
Pubblicazione: (2015-01-01)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
di: Betts, G, et al.
Pubblicazione: (2012)

Tuberculosis vaccines: current status and future prospects.
di: Fletcher, H, et al.
Pubblicazione: (2006)

Tuberculosis vaccines: beyond bacille Calmette–Guérin
di: McShane, H
Pubblicazione: (2011)

Tuberculosis vaccines: Beyond bacilli Calmette-Guérin
di: McShane, H
Pubblicazione: (2011)

Erratum: Viral booster vaccines improve mycobacterium bovis BCG-induced protection against bovine tuberculosis
di: Vordermeier, H, et al.
Pubblicazione: (2011)

Vaccine strategies against tuberculosis.
di: Mcshane, H
Pubblicazione: (2009)

Challenges in developing a controlled human tuberculosis challenge model
di: Jackson, S, et al.
Pubblicazione: (2022)

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
di: Satti, I, et al.
Pubblicazione: (2022)

Saponin TQL1055 adjuvant-containing vaccine confers protection upon Mycobacterium tuberculosis challenge in mice
di: Mushtaq Ahmed, et al.
Pubblicazione: (2024-12-01)

Developing an improved vaccine against tuberculosis.
di: Mcshane, H
Pubblicazione: (2004)

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG mediated protection in a murine model of tuberculosis
di: McShane, H, et al.
Pubblicazione: (2016)

Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis.
di: Ana Paula Junqueira-Kipnis, et al.
Pubblicazione: (2013-01-01)

Improving tuberculosis vaccine trial efficiency: a tough nut to crack
di: McShane, H
Pubblicazione: (2023)

Why don’t we have an effective tuberculosis vaccine yet?
di: Davenne, T, et al.
Pubblicazione: (2016)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
di: Meyer, J, et al.
Pubblicazione: (2013)

A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guérin
di: Minassian, A, et al.
Pubblicazione: (2012)

A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin.
di: Minassian, A, et al.
Pubblicazione: (2012)

Attenuated Mycobacterium tuberculosis vaccine protection in a low-dose murine challenge model
di: Samuel J. Vidal, et al.
Pubblicazione: (2023-06-01)